You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 3044 results
  1. Home Monitoring of Metabolic Disorders

    SBC: SEQUITUR HEALTH CORP            Topic: NICHD

    PROJECT SUMMARY This proposal is submitted in direct response to NOT-HD-22-009 Notice of Special Interest (NOSI): Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities [IDD] (R43/R44). Persons of all ages with certain metabolic disorders are at-risk for metabolic crises when a certain metabolite accumulates, whi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke

    SBC: NUVOX PHARMA, L.L.C.            Topic: NINDS

    ABSTRACT / PROJECT SUMMARY Stroke affects more than 795,000 patients per year in the US and kills approximately 40,000. Long-term medical care expense for stroke in the US, costs over $34B per year. Large vessel occlusion (LVO) stroke accounts for almost 40% of ischemic strokes but causes 95% of mortality and 62% of long-term dependence. Mechanical thrombectomy (MT), or a combination of MT and tPA ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Scalable MXene Synthesis for Aerospace Applications

    SBC: BALLYDEL TECHNOLOGIES INC.            Topic: AF21ATCSO2

    During the Phase II effort, Ballydel Technologies will develop scalable and safe processes for the manufacture of MAX phase and MXene powders in 1Kg batch sizes.  Additionally, our team will implement commercial-scale mixing procedures for the production

    STTR Phase II 2023 Department of DefenseAir Force
  4. A Prototype for Geosynchronous Satellite Surveillance using Passive RF Collection

    SBC: RINCON RESEARCH CORPORATION            Topic: SF224D007

    As is well noted, GEODSS telescopes are unable to perform their primary space surveillance mission during daytime and weather outages. Passive RF provides a needed augmentation to the GEODSS mission with its ability to maintain custody and support routine

    SBIR Phase II 2023 Department of DefenseAir Force
  5. DIALR Phase II

    SBC: PRIME SOLUTIONS GROUP, INCORPORATED            Topic: OSD221002

    The pace of remotely sensed data collection is increasing exponentially while the skilled workforce that is available to analyze and interpret the data is not. Artificial Intelligence (AI) offers a technology pathway to automation which promises to rapidly reduce the gap between data and information products and services. However, AI techniques require massive quantities of labeled data to train m ...

    SBIR Phase II 2023 Department of DefenseNational Geospatial-Intelligence Agency
  6. Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies

    SBC: CND LIFE SCIENCES, INC.            Topic: 105

    PROJECT SUMMARY A group of devastating diseases, collectively termed synucleinopathies, affect over 2 million people in the U.S., carry significant morbidity, high mortality and enormous associated health care costs. Synucleinopathies are characterized by the abnormal deposition of a misfolded protein, phosphorylated α−synuclein (P-SYN), within the central and peripheral nervous systems. Synucl ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Small Molecule Inhibitor of Fortilin for Atherosclerosis Treatment and Prevention

    SBC: FORTISCIENCE, INC.            Topic: NHLBI

    Project Summary Project Title: Development of a Small Molecule Inhibitor of Fortilin for Atherosclerosis Treatment and Prevention. Atherosclerosis affects more than 18 million Americans and is a major cause of cardiovascular diseases and acute cardiovascular events, such as heart attack and stroke. Current interventions include changes to diet and exercise, smoking cessation, and treatment with st ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Amino Acids and Pediatric Hepatic Steatosis

    SBC: THE AMINO COMPANY LLC            Topic: 300

    7. Project Summary/Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in North America (1). Hepatic steatosis (HS) is the hallmark of NAFLD (2). NAFLD may transition in sub-groups to chronic inflammation (non- alcoholic steatohepatitis, NASH), and ultimately to cirrhosis. HS is prevalent in all stages of NAFLD. 3-10% of all children in the US and 40-70% of obese ch ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. PET Imaging of Damaging Neuroinflammation in Alzheimer's Disease

    SBC: EINSENCA INC.            Topic: NIA

    Alzheimer's disease (AD) is a devastating and progressive disease without a cure. Neuroinflammation is now recognized as a key early event in the development of AD. Aberrant neuroinflammatory response activates immune cells that can increase oxidative stress, and oxidative stress can directly damage neurons and axons, cause demyelination, and break down the blood-brain barrier (BBB). Thus, damagin ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: 300

    ABSTRACT Inflammatory bowel disease (IBD) is a debilitating disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A0 R42 STTR application focuses on a highly novel humanized monoclonal antibody (mAb), ALT-100, to target and neutralize eNAMPT (extracellular nicotinamide phosphoribosyltransferase), a damage-associated molecular pattern protein ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government